Therapeutic approach targeting the proteins involved in mechanisms of multidrug resistance
Tsuruo, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(4 Pt 2-1): 1026-1030
1988
ISSN/ISBN: 0385-0684 PMID: 2898920 Document Number: 323973
Recently, the mechanisms of multidrug resistance have been partly elucidated. Based on these resistant mechanisms, therapeutic approaches targeting the proteins involved in the mechanisms of multidrug resistance are under investigation. These include therapies with monoclonal antibodies, drug resistant genes and agents interacting with the proteins of resistant tumor cells.
Document emailed within 1 workday
Related Documents
Naramoto, H.; Uematsu, T.; Uchihashi, T.; Doto, R.; Matsuura, T.; Usui, Y.; Uematsu, S.; Li, X.; Takahashi, M.; Yamaoka, M.; Furusawa, K. 2007: Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines International Journal of Oncology 30(2): 393-401Tan, Y-hong.; Yang, C-zheng.; Zhao, C-hua.; Qi, J.; Peng, H.; Wang, J-xiang.; Zhou, Y.; Xiao, Y.; Lan, L. 2004: Identification of differentially expressed genes involved in multidrug resistance in K562/A02 by cDNA microarray Zhonghua Zhong Liu Za Zhi 26(6): 328-332
Volm, M.; Bak, M.; Efferth, T.; Mattern, J. 1988: Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins Anticancer Research 8(6): 1169-1178
Zhou, D.C.; Zittoun, R.; Marie, J.P. 1995: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 9(10): 1661-1666
Tsuruo, T. 1988: Therapeutic approaches for multidrug resistance Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(10): 2848-2852
Scheltema, J.M.; Romijn, J.C.; van Steenbrugge, G.J.; Schröder, F.H.; Mickisch, G.H. 2001: Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells Anticancer Research 21(5): 3161-3166
Takemura, Y.; Kobayashi, H.; Miyachi, H. 1998: Mechanisms of multidrug resistance in tumor cells and analytical methods for its detection Rinsho Byori. Japanese Journal of Clinical Pathology 46(8): 745-758
Hayward, C.M.; Griffin, G.E. 1994: Antibiotic resistance: the current position and the molecular mechanisms involved British Journal of Hospital Medicine 52(9): 473-478
Salmon, S.E.; Dalton, W.S. 1996: Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis Journal of Rheumatology. Supplement 44: 97-101
Saint, F.; Patard, J.J.; Salomon, L.; Alamé, W.; Cicco, A.; Abbou, C.C.; Chopin, D. 2000: Mechanisms of action of BCG: towards a new individualized therapeutic approach? Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 10(6): 1118-1126
Paduch, R.; Jakubowicz-Gil, J.; Niedziela, P. 2010: Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11) Indian Journal of Experimental Biology 48(4): 354-364
Abbaszadegan, M.R.; Cress, A.E.; Futscher, B.W.; Bellamy, W.T.; Dalton, W.S. 1996: Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers Cancer Research 56(23): 5435-5442
Bhuyan, B.K.; Smith, K.S.; Kelly, R.C.; Adams, E.G.; Abraham, I.; Sampson, K.E. 1993: Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin Cancer Research 53(6): 1354-1359
Weber, J.M.; Sircar, S.; Horvath, J.; Dion, P. 1989: Non-p-glycoprotein-mediated multidrug resistance in detransformed rat cells selected for resistance to methylglyoxal bis(guanylhydrazone) Cancer Research 49(21): 5779-5783
Itoh, Y.; Tamai, M.; Yokogawa, K.; Nomura, M.; Moritani, S.; Suzuki, H.; Sugiyama, Y.; Miyamoto, K-ichi. 2002: Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells Anticancer Research 22(3): 1649-1653
Eguchi, T.; Tezuka, T.; Miyoshi, S.; Yamanashi, Y. 2017: Molecular mechanisms underlying the formation and maintenance of neuromuscular junctions and a possible therapeutic approach Clinical Calcium 27(3): 413-419
Akiyama, S.; Yoshimura, A.; Kikuchi, H.; Kamiwatari, M.; Nagata, Y.; Seto, K.; Sakota, R.; Utsunomiya, A.; Hanada, S.; Hashimoto, S. 1989: A molecular basis for multidrug resistance and reversal of the resistance Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt: 2-1): 1266-1272
Singer, C.F.; Hudelist, G.; Galid, A.; Kubista, E. 2003: Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment Drugs of Today 39(12): 917-926
Volm, M.; Bak, M.; Mattern, J. 1988: Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins Arzneimittel-Forschung 38(8): 1189-1193
Tamai, M.; Ito, Y.; Mirura, H.; Tsukada, H.; Yokogawa, K.; Nomura, M.; Moritani, S.; Miyamoto, K.-I. 2003: Conjugated bilirubin induces multidrug resistance-associated protein 2 mRNA expression and in vivo cisplatin resistance in rat hepatoma AH66 cells Anticancer Research 23(6c): 4781-4787